Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Current Deferred Revenue: 2009-2011

Historic Current Deferred Revenue for Madrigal Pharmaceuticals (MDGL) over the last 3 years, with Sep 2011 value amounting to $3.3 million.

  • Madrigal Pharmaceuticals' Current Deferred Revenue fell 27.76% to $3.3 million in Q3 2011 from the same period last year, while for Sep 2011 it was $3.3 million, marking a year-over-year decrease of 27.76%. This contributed to the annual value of $4.6 million for FY2010, which is 103.95% up from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $3.3 million for Q3 2011, which was down 25.71% from $4.4 million recorded in Q2 2011.
  • Madrigal Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $120.6 million during Q2 2009, with a 5-year trough of -$115.6 million in Q4 2009.
  • Moreover, its 3-year median value for Current Deferred Revenue was $4.6 million (2011), whereas its average is $3.8 million.
  • Data for Madrigal Pharmaceuticals' Current Deferred Revenue shows a peak YoY increase of 104.00% (in 2010) and a maximum YoY decrease of 96.21% (in 2010) over the last 5 years.
  • Quarterly analysis of 3 years shows Madrigal Pharmaceuticals' Current Deferred Revenue stood at -$115.6 million in 2009, then skyrocketed by 103.95% to $4.6 million in 2010, then fell by 27.76% to $3.3 million in 2011.
  • Its Current Deferred Revenue stands at $3.3 million for Q3 2011, versus $4.4 million for Q2 2011 and $4.6 million for Q1 2011.